search
Back to results

ENABLE (Educate, Nurture, Advise, Before Life Ends) Intervention for Heart Failure (HF) Patients and Their Caregivers in Singapore (ENABLE-HF-SG)

Primary Purpose

Heart Failure

Status
Recruiting
Phase
Not Applicable
Locations
Singapore
Study Type
Interventional
Intervention
Immediate ENABLE nurse coaching, on top of usual care
Usual Care
Sponsored by
National Cancer Centre, Singapore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Heart Failure focused on measuring Palliative care, Patients, Caregivers, Distress thermometer (DT), Integrated Palliative Care Outcome Scale (IPOS), ENABLE (Educate, Nurture, Advise, Before Life Ends)

Eligibility Criteria

21 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Inclusion criteria for patients:

    1. 21 years or older.
    2. Able to communicate in English or Chinese.
    3. Have a diagnosis of HF (stage C or D) by the American College of Cardiology guidelines and be of New York Heart Association (NYHA) stage 2, 3 or 4 functional statuses.
    4. Have an expected prognosis of at least 6 months.
    5. Be on disease directed HF management.
    6. Have had a hospitalization event within 6 months prior to recruitment.
  • Inclusion criteria for caregivers:

    1. 21 years or older.
    2. Able to communicate in English or Chinese.
    3. Is a direct family caregiver of the patient.

Exclusion Criteria:

  • Exclusion criteria for patients:

    1. Patients who are unable to give informed consent
    2. Patients who are already known to a palliative care service.
  • Exclusion criteria for caregivers:

    1. Caregivers who are unable to give informed consent.
    2. Caregivers who are domestic helpers.

Sites / Locations

  • National Cancer Centre SingaporeRecruiting
  • National Heart Centre SingaporeRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Immediate

Wait-list (delayed)

Arm Description

Participants in the intervention arm will start on the ENABLE program at point of randomization.

Participants on wait-list will start ENABLE 6 months after randomization.

Outcomes

Primary Outcome Measures

Feasibility of trial procedures - percentage of patients and caregivers that are recruited, successfully randomized, and able to complete the ENABLE program
The percentage of eligible participants that are able to be recruited, randomized and subsequently complete the ENABLE program will be calculated.
Acceptability of ENABLE program - through completion of the client satisfaction questionnaire (CSQ-4)
The total score of the CSQ-4 will be calculated for each participant. For the assessment of acceptability, scores from participants from both intervention and wait-list control groups will be pooled, except for participants who drop out prior to starting ENABLE (for reasons unrelated to the ENABLE program). The minimum expected score per participant is 4, and the maximum expected score per participant is 16. A higher score indicates higher satisfaction.
The possible efficacy of the ENABLE program- through evaluating change in patient quality of life (QOL) at 6 months as compared to baseline (assessed using the Kansas City Cardiomyopathy Questionnaire - KCCQ)
For the primary outcome of change in patient QOL, we will compare the change in the QOL from baseline to 6 months post randomization in the intervention group versus the change from baseline to 6 months post randomization in the control group. The difference between the intervention and wait-list control arm will be quantified as Cohen's d effect sizes to get an initial estimate of the efficacy of ENABLE. The minimum score on KCCQ is 0 and maximum possible score is 100. A higher score indicates a better quality of life.

Secondary Outcome Measures

Full Information

First Posted
January 2, 2022
Last Updated
February 28, 2023
Sponsor
National Cancer Centre, Singapore
Collaborators
Ministry of Health, Singapore, National Medical Research Council (NMRC), Singapore
search

1. Study Identification

Unique Protocol Identification Number
NCT05211882
Brief Title
ENABLE (Educate, Nurture, Advise, Before Life Ends) Intervention for Heart Failure (HF) Patients and Their Caregivers in Singapore
Acronym
ENABLE-HF-SG
Official Title
Pilot Wait-list Randomized Controlled Trial of the ENABLE (Educate, Nurture, Advise, Before Life Ends) Intervention for Heart Failure (HF) Patients and Their Caregivers in Singapore
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 14, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Centre, Singapore
Collaborators
Ministry of Health, Singapore, National Medical Research Council (NMRC), Singapore

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To pilot a culturally adapted version of ENABLE (6-month program) for Heart Failure (HF) patients and caregivers in the inpatient and outpatient setting in Singapore. The investigators aim to determine the feasibility of trial procedures and assess the acceptability and preliminary efficacy of ENABLE with a randomized wait-list controlled trial design.
Detailed Description
Palliative care improves quality of life (QOL) of patients and their caregivers. The ENABLE (Educate, Nurture, Advise Before Life Ends) intervention is a novel, nurse-led, structured, palliative care coaching program, developed in the United States for patients (and caregivers of patients) facing serious illnesses. It aims to empower patients and caregivers to manage their problems, prepare for the future, and has showed beneficial impact on patient and caregiver QOL. The ENABLE coaching program is a potentially scalable means of delivering palliative care to a large population; as compared to the current local model of palliative care provision, which uses a resource intensive multidisciplinary care model that is not easily scalable and therefore unlikely to meet the growing needs of HF patients and caregivers locally. However, it is unclear if the ENABLE HF program will be culturally acceptable and efficacious in Singapore, in view of differing socio-cultural attitudes and expectations regarding healthcare and treatments, decision making and care planning. Overall aim - To pilot a culturally adapted version of ENABLE (6-month program) for HF patients and caregivers in the inpatient and outpatient setting in Singapore. Specific Aim 1 - Assessment of feasibility of trial procedures in the local HF population. Intervention arm participants will start on ENABLE after randomization, while wait-list participants will start on ENABLE after 6 months. The investigators will evaluate the percentage of eligible participant dyads who consent to participate and who are able to complete the ENABLE program. The investigators will also explore the percentage completion rate of patient and caregiver reported outcome measures. - Hypothesis: The investigators hypothesize a-priori that 80% of eligible participant dyads will consent to participate and 80% of eligible participant dyads will be able to complete the ENABLE program. Specific aim 2 - Assessment of acceptability of ENABLE. The investigators aim to study the acceptability of ENABLE to all patient-caregiver dyads. This will be done through evaluating the total scores of a satisfaction survey of all participants at the end of ENABLE. - Hypothesis: The investigators hypothesize that at least 80% of all participants will find the ENABLE program acceptable. Specific aim 3 - Assessment of the possible efficacy of ENABLE. The investigators will evaluate whether there is an efficacy signal that indicates ENABLE may improve patient QOL in the local HF context. - Hypothesis: The investigators hypothesize that patient participants randomized to the intervention arm will have more improvement in their mean QOL scores after 6 months as compared to the wait-list control group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
Keywords
Palliative care, Patients, Caregivers, Distress thermometer (DT), Integrated Palliative Care Outcome Scale (IPOS), ENABLE (Educate, Nurture, Advise, Before Life Ends)

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Immediate
Arm Type
Experimental
Arm Description
Participants in the intervention arm will start on the ENABLE program at point of randomization.
Arm Title
Wait-list (delayed)
Arm Type
Experimental
Arm Description
Participants on wait-list will start ENABLE 6 months after randomization.
Intervention Type
Other
Intervention Name(s)
Immediate ENABLE nurse coaching, on top of usual care
Intervention Description
Participants in the intervention arm will start on the ENABLE program at point of randomization
Intervention Type
Other
Intervention Name(s)
Usual Care
Intervention Description
Participants on wait-list will continue on usual care and only start ENABLE 6 months after randomization.
Primary Outcome Measure Information:
Title
Feasibility of trial procedures - percentage of patients and caregivers that are recruited, successfully randomized, and able to complete the ENABLE program
Description
The percentage of eligible participants that are able to be recruited, randomized and subsequently complete the ENABLE program will be calculated.
Time Frame
6 months.
Title
Acceptability of ENABLE program - through completion of the client satisfaction questionnaire (CSQ-4)
Description
The total score of the CSQ-4 will be calculated for each participant. For the assessment of acceptability, scores from participants from both intervention and wait-list control groups will be pooled, except for participants who drop out prior to starting ENABLE (for reasons unrelated to the ENABLE program). The minimum expected score per participant is 4, and the maximum expected score per participant is 16. A higher score indicates higher satisfaction.
Time Frame
6 months.
Title
The possible efficacy of the ENABLE program- through evaluating change in patient quality of life (QOL) at 6 months as compared to baseline (assessed using the Kansas City Cardiomyopathy Questionnaire - KCCQ)
Description
For the primary outcome of change in patient QOL, we will compare the change in the QOL from baseline to 6 months post randomization in the intervention group versus the change from baseline to 6 months post randomization in the control group. The difference between the intervention and wait-list control arm will be quantified as Cohen's d effect sizes to get an initial estimate of the efficacy of ENABLE. The minimum score on KCCQ is 0 and maximum possible score is 100. A higher score indicates a better quality of life.
Time Frame
6 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Inclusion criteria for patients: 21 years or older. Able to communicate in English or Chinese. Have a diagnosis of HF (stage C or D) by the American College of Cardiology guidelines and be of New York Heart Association (NYHA) stage 2, 3 or 4 functional statuses. Have an expected prognosis of at least 6 months. Be on disease directed HF management. Have had a hospitalization event within 6 months prior to recruitment. Inclusion criteria for caregivers: 21 years or older. Able to communicate in English or Chinese. Is a direct family caregiver of the patient. Exclusion Criteria: Exclusion criteria for patients: Patients who are unable to give informed consent Patients who are already known to a palliative care service. Exclusion criteria for caregivers: Caregivers who are unable to give informed consent. Caregivers who are domestic helpers.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dr Shirlyn Neo, MBBS, MRCP (UK), MMed, FAMS
Phone
+65 64368183
Email
shirlyn.neo.h.s@singhealth.com.sg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr Shirlyn Neo, MBBS, MRCP (UK), MMed, FAMS
Organizational Affiliation
National Cancer Centre, Singapore
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Cancer Centre Singapore
City
Singapore
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Shirlyn Neo, MBBS, MRCP (UK), MMed, FAMS
Phone
+65 64368183
Facility Name
National Heart Centre Singapore
City
Singapore
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr David Sim, MBBS, MMed (Int Med), MRCP(UK)
Phone
+65 67048965

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

ENABLE (Educate, Nurture, Advise, Before Life Ends) Intervention for Heart Failure (HF) Patients and Their Caregivers in Singapore

We'll reach out to this number within 24 hrs